File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Open label trial with vigabatrin in children with intractable epilepsy

TitleOpen label trial with vigabatrin in children with intractable epilepsy
Authors
KeywordsChildren
Intractable epilepsy
Vigabatrin
Issue Date1995
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/braindev
Citation
Brain And Development, 1995, v. 17 n. 4, p. 249-252 How to Cite?
AbstractThirty children (20 males, 10 females) with intractable epilepsy received vigabatrin (VGB) as an open label basis to preexisting antiepileptic drugs. The seizure types consisted of generalized tonic clonic seizure [10], complex partial seizure [8], myoclonic seizure [7], and mixed type with simple partial seizure, complex partial seizure and/or generalized seizure [5]. The cause of the epilepsy was cryptogenic in 16 and symptomatic in 12. The current dosage regime of anticonvulsants were maintained during the trial period. VGB at 40-80 mg/kg/day were titrated according to the clinical response for a period of 2-24 months. The result of treatment was categorized as 'responders' with 13 (43%) having 50-75% reduction of seizure frequency; and 'non-responders' which consisted of 17 children. There was no relationship between outcome of VBG add-on therapy and the sex, age of onset, type of seizure, type of epileptic syndrome, etiology, associated neurological abnormality, mental retardation or abnormal brain CT/MRI findings.
Persistent Identifierhttp://hdl.handle.net/10722/143591
ISSN
2015 Impact Factor: 1.785
2015 SCImago Journal Rankings: 0.840
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, Ven_HK
dc.date.accessioned2011-12-12T03:52:09Z-
dc.date.available2011-12-12T03:52:09Z-
dc.date.issued1995en_HK
dc.identifier.citationBrain And Development, 1995, v. 17 n. 4, p. 249-252en_HK
dc.identifier.issn0387-7604en_HK
dc.identifier.urihttp://hdl.handle.net/10722/143591-
dc.description.abstractThirty children (20 males, 10 females) with intractable epilepsy received vigabatrin (VGB) as an open label basis to preexisting antiepileptic drugs. The seizure types consisted of generalized tonic clonic seizure [10], complex partial seizure [8], myoclonic seizure [7], and mixed type with simple partial seizure, complex partial seizure and/or generalized seizure [5]. The cause of the epilepsy was cryptogenic in 16 and symptomatic in 12. The current dosage regime of anticonvulsants were maintained during the trial period. VGB at 40-80 mg/kg/day were titrated according to the clinical response for a period of 2-24 months. The result of treatment was categorized as 'responders' with 13 (43%) having 50-75% reduction of seizure frequency; and 'non-responders' which consisted of 17 children. There was no relationship between outcome of VBG add-on therapy and the sex, age of onset, type of seizure, type of epileptic syndrome, etiology, associated neurological abnormality, mental retardation or abnormal brain CT/MRI findings.en_HK
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/braindeven_HK
dc.relation.ispartofBrain and Developmenten_HK
dc.subjectChildrenen_HK
dc.subjectIntractable epilepsyen_HK
dc.subjectVigabatrinen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAge of Onseten_US
dc.subject.meshAnticonvulsants/adverse effects/*therapeutic useen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshEpilepsy/complications/*drug therapy/psychologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMagnetic Resonance Imagingen_US
dc.subject.meshMaleen_US
dc.subject.meshTomography, X-Ray Computeden_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVigabatrinen_US
dc.subject.meshgamma-Aminobutyric Acid/adverse effects/*analogs & derivatives/therapeuticen_US
dc.titleOpen label trial with vigabatrin in children with intractable epilepsyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, V:vcnwong@hku.hken_HK
dc.identifier.authorityWong, V=rp00334en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/0387-7604(95)00038-Den_HK
dc.identifier.pmid7503385en_HK
dc.identifier.scopuseid_2-s2.0-0029113503en_HK
dc.identifier.volume17en_HK
dc.identifier.issue4en_HK
dc.identifier.spage249en_HK
dc.identifier.epage252en_HK
dc.identifier.isiWOS:A1995RR68100003-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridWong, V=7202525632en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats